Bayer Taps Stanford AI Startup Phylo (Biomni Lab) for Drug Discovery After $13.5M Seed
RichardsonDx · x · 2026-10-25
Pharma giant Bayer is working with Phylo, a Stanford AI startup whose product Biomni Lab—built on the open-source Biomni agent—helps find new drugs, following a $13.5M seed round.
The agent reads papers, runs analyses, and assembles evidence for researchers. Per the accompanying figure, Biomni provides a unified biomedical action space spanning 25 disciplines (genomics, pathology, pharmacology, etc.), integrating 105 software packages, 150 specialized biology tools, and 59 databases to plan and execute research workflows such as processing expression data and testing oncogenic pathway enrichment.
Related event: Bayer Partners with Stanford Startup Phylo to Speed Up Drug Discovery(2 posts)→
More from Venture
- Founders mull $100M Indian deeptech fund to fix VC risk aversion — jajoosam · 2026-10-25
- Why Databricks is beating Snowflake: mission-driven culture vs. competing interests — thedealdirector · 2026-10-25
- Inference abundance beyond frontier labs is key to the AI startup ecosystem — BenBajarin · 2026-10-25
- Lex Sokolin podcast: AI, Crypto and the rise of on-chain AI agents — LexSokolin · 2026-10-25
- Grok ranks side hustles: SEO niche sites beat crypto and creator income — gefei55 · 2026-10-25
- Polymarket volumes hit record $1B+ in a single day — SiddDevs · 2026-10-25